Effects of metformin on FOXM1 expression andon the biological behavior of acute leukemia cell lines

Molecular Medicine Reports

Volumn 10, Issue 6, 2014, Pages 3193-3198

  Zhang, Bing ^a,b   Liu, Long Long ^c   Mao, Xia ^a   Zhang, Dong Hua ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b AFFILIATED HOSPITAL OF NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

^c WUHAN GENERAL HOSPITAL OF GUANGZHOU COMMAND   (China)

Author keywords

Acute myeloid leukemia; FOXM1; Metformin; mTOR; Thiostrepton

Indexed keywords

MAMMALIA;

FORKHEAD TRANSCRIPTION FACTOR; FOXM1 PROTEIN, HUMAN; METFORMIN; MTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE; THIOSTREPTON;

APOPTOSIS; CELL CYCLE CHECKPOINT; CELL PROLIFERATION; CELL TRANSFORMATION; DOWN REGULATION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HUMAN; LEUKEMIA; TUMOR CELL LINE;

APOPTOSIS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; DOWN-REGULATION; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LEUKEMIA; METFORMIN; THIOSTREPTON; TOR SERINE-THREONINE KINASES;

EID: 84914146109     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2014.2629     Document Type: Article

References (24)

1. Wang Z, Banerjee S, Kong D, Li Y and Sarkar FH: Down-regulation of Forkhead Box M1 transcription factor leads to the inhibition of invasion and angiogenesis of pancreatic cancer cells. Cancer Res 67: 8293-8300, 2007.
2. Wu QF, Liu C, Tai MH, et al: Knockdown of FoxM1 by siRNA interference decreases cell proliferation, induces cell cycle arrest and inhibits cell invasion in MHCC-97H cells in vitro. Acta Pharmacol Sin 31: 361-366, 2010.
3. Ahmad A, Wang Z, Kong D, et al: FoxM1 down-regulation leads to inhibition of proliferation, migration and invasion of breast cancer cells through the modulation of extra-cellular matrix degrading factors. Breast Cancer Res Treat 122: 337-346, 2010.
4. Nakamura S, Hirano I, Okinaka K, et al: The FOXM1 transcriptional factor promotes the proliferation of leukemia cells through modulation of cell cycle progression in acute myeloid leukemia. Carcinogenesis 31: 2012-2021, 2010.
5. Lee MS, Hsu CC, Wahlqvist ML, Tsai HN, Chang YH and Huang YC: Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800, 000 individuals. BMC Cancer 11: 20, 2011.
6. Green AS, Chapuis N, Lacombe C, Mayeux P, Bouscary D and Tamburini J: LKB1/AMPK/mTOR signaling pathway in hematological malignancies: from metabolism to cancer cell biology. Cell Cycle 10: 2115-2120, 2011.
7. Spender LC and Inman GJ: Phosphoinositide 3-kinase/AKT/mTORC1/2 signaling determines sensitivity of Burkitt's lymphoma cells to BH3 mimetics. Mol Cancer Res 10: 347-359, 2012.
8. Feng Y, Ke C, Tang Q, et al.: Metformin promotes autophagy and apoptosis in esophageal squamous cell carcinoma by downregulating Stat3 signaling. Cell Death Dis 5: e1088, 2014.
9. Warren M, Luthra R, Yin CC, et al: Clinical impact of change of FLT3 mutation status in acute myeloid leukemia patients. Mod Pathol 25: 1405-1412, 2012.
10. Hegde NS, Sanders DA, Rodriguez R and Balasubramanian S: The transcription factor FOXM1 is a cellular target of the natural product thiostrepton. Nat Chem 3: 725-731, 2011.
11. Wonsey DR and Follettie MT: Loss of the forkhead transcription factor FoxM1 causes centrosome amplification and mitotic catastrophe. Cancer Res 65: 5181-5189, 2005.
12. Bhat UG, Halasi M and Gartel AL: Thiazole antibiotics target FoxM1 and induce apoptosis in human cancer cells. PLoS One 4: e5592, 2009.
13. Kiyoi H, Yanada M and Ozekia K: Clinical significance of FLT3 in leukemia. Int J Hematol 82: 85-92, 2005.
14. Yanada M, Matsuo K, Suzuki T, Kiyoi H and Naoe T: Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a meta-analysis. Leukemia 19: 1345-1349, 2005.
15. Frohling S, Schlenk RF, Breitruck J, et al.: Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood 100: 4372-4380, 2002.
16. Green AS, Chapuis N, Maciel TT, et al: The LKB1/AMPK signaling pathway has tumor suppressor activity in acute myeloid leukemia through the repression of mTOR-dependent oncogenic mRNA translation. Blood 116: 4262-4273, 2010.
17. Memmott RM, Mercado JR, Maier CR, Kawabata S, Fox SD and Dennis PA: Metformin prevents tobacco carcinogen - induced lung tumorigenesis. Cancer Prev Res (Phila) 3: 1066-1076, 2010.
18. Oliveras-Ferraros C, Cufi S, Vazquez-Martin A, et al: Micro(mi)RNA expression profile of breast cancer epithelial cells treated with the anti-diabetic drug metformin: induction of the tumor suppressor miRNA let-7a and suppression of the TGFβ-induced oncomiR miRNA-181a. Cell Cycle 10: 1144-1151, 2011.
19. Hirsch HA, Iliopoulos D, Tsichlis PN and Struhl K: Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res 69: 7507-7511, 2009.
20. Wang X, Hung NJ and Costa RH: Earlier expression of the transcription factor HFH-11B diminishes induction of p21(CIP1/WAF1) levels and accelerates mouse hepatocyte entry into S-phase following carbon tetrachloride liver injury. Hepatology 33: 1404-1414, 2001.
21. Wang X, Krupczak-Hollis K, Tan Y, Dennewitz MB, Adami GR and Costa RH: Increased hepatic Forkhead Box M1B (FoxM1B) levels in old-aged mice stimulated liver regeneration through diminished p27Kip1 protein levels and increased Cdc25B expression. J Biol Chem 277: 44310-44316, 2002.
22. Sun DF, Zhang YJ, Tian XQ, Chen YX and Fang JY: Inhibition of mTOR signalling potentiates the effects of trichostatin A in human gastric cancer cell lines by promoting histone acetylation. Cell Biol Int 38: 50-63, 2014.
23. MacKenzie MJ, Ernst S, Johnson C and Winquist E: A phase I study of temsirolimus and metformin in advanced solid tumours. Invest New Drugs 30: 647-652, 2012.
24. Martin-Castillo B, Dorca J, Vazquez-Martin A, et al: Incorporating the antidiabetic drug metformin in HER2-positive breast cancer treated with neo-adjuvant chemotherapy and trastuzumab: an ongoing clinical-translational research experience at the Catalan Institute of Oncology. Ann Oncol 21: 187-189, 2010.